This is a summary of the European public assessment report (EPAR) for Bonviva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Bonviva.
Therapeutic Indication
### Therapeutic indication Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.
Therapeutic Area (MeSH)
N/AATC Code
M05BA06
ATC Item
ibandronic acid
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| ibandronic acid | N/A | 伊班膦酸钠 |
EMA Name
Bonviva
Medicine Name
Bonviva
Aliases
N/ANo risk management plan link.
